Molecular Omics

RESEARCH ARTICLE

Check for updates

Cite this: *Mol. Omics*, 2020, **16**, 231

Received 29th November 2019, Accepted 10th March 2020

DOI: 10.1039/c9mo00174c

rsc.li/molomics

1. Introduction

Glycomics is an emerging omics field. The majority of proteins are glycosylated and glycomics changes may well be a hallmark of human disease.¹ The structural complexity of glycans, however, has slowed down the development of high-throughput quantification methods, and technical improvements are still ongoing. Keeping pace with technological progress we here examine appropriate handling of glycomics data in large sample studies. The motivating example of the present work is based

Choosing proper normalization is essential for discovery of sparse glycan biomarkers†

Rapid progress in high-throughput glycomics analysis enables the researchers to conduct large sample studies. Typically, the between-subject differences in total abundance of raw glycomics data are very large, and it is necessary to reduce the differences, making measurements comparable across samples. Essentially there are two ways to approach this issue: row-wise and column-wise normalization. In glycomics, the differences per subject are usually forced to be exactly zero, by scaling each sample having the sum of all glycan intensities equal to 100%. This total area (row-wise) normalization (TA) results in so-called compositional data, rendering many standard multivariate statistical methods inappropriate or inapplicable. Ignoring the compositional nature of the data, moreover, may lead to spurious results. Alternatively, a log-transformation to the raw data can be performed prior to columnwise normalization and implementing standard statistical tools. Until now, there is no clear consensus on the appropriate normalization method applied to glycomics data. Nor is systematic investigation of impact of TA on downstream analysis available to justify the choice of TA. Our motivation lies in efficient variable selection to identify glycan biomarkers with regard to accurate prediction as well as interpretability of the model chosen. Via extensive simulations we investigate how different normalization methods affect the performance of variable selection, and compare their performance. We also address the effect of various types of measurement error in glycans: additive, multiplicative and two-component error. We show that when sample-wise differences are not large row-wise normalization (like TA) can have deleterious effects on variable selection and prediction.

> on data from Orkney Islands in Scotland,² where we assess prediction of age from immunoglobulin G (IgG) glycans. Fig. 1 shows twenty four glycans bound to IgG measured by ultraperformance liquid chromatography (UPLC). It is reported that IgG glycosylation appears to be closely linked with chronological and biological ages.²⁻⁴ Prior to exploring the potential of glycan biomarkers of ageing, several steps of data pre-processing are required (Fig. 2). Our interest here is to minimize unwanted biases and variances. In this paper pre-processing refers to various techniques used for extracting clean data from raw instrumental data, and pre-treatment to methods that transform the cleaned raw data for downstream statistical analysis.⁵ Normalization of the raw data is needed to transform glycomics measurements or abundances to comparable scales, and improper normalization methods can significantly impair the data.^{6,7} In this work we systematically investigate the impact of different normalization methods on variable selection using lasso regression with glycan covariates.

> In general, between-subject differences in total abundance of raw glycomics data are large, and even technical replicates show substantial differences due to measurement errors. To reduce these differences (or variances), applying a log-transformation



View Article Online

^a Department of Biostatistics and Research Support, University Medical Center

Utrecht, Utrecht, Netherlands. E-mail: h.w.uh@umcutrecht.nl

^b Genos Glycoscience Research Laboratory, Zagreb, Croatia

^c MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

^d University of Split, Faculty of Science, Split, Croatia


^e Intellomics Ltd, Croatia


^fFaculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia


^g Biosystems Data Analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands

^h Department of Statistics, University of Leeds, Leeds, UK

 $[\]dagger$ Electronic supplementary information (ESI) available. See DOI: 10.1039/ c9mo00174c









to the cleaned raw data is by far the easiest way, as in other omics data analysis. Traditionally, however, the difference in total abundance per subject is forced to be exactly zero by scaling each sample to have the sum of all glycan intensities equal to 1 (or 100%). This results in so-called compositional data, also present in microbiome data analysis. Until now, there is no clear consensus on the appropriate normalization method for glycomics data.

The compositional nature of the data renders many standard multivariate statistical methods inappropriate or inapplicable, and the complications from such data are well recognized in the statistics literature.^{8,9} For example, one cannot simply calculate




Fig. 3 Correlation structure of immunoglobulin G glycan data. The heatmap depicts the pair-wise Spearman's rank correlation coefficients: the colours blue and red representing negative and positive correlation, respectively. The darker the colour, the stronger the correlation. From left to right and top to bottom: (a) clean data, (b) log (clean data), (c) TA, (d) logTA, (e) RP, (f) MQ, (g) MS, and (h) MQN. The log-transformation ((a) vs. (b), and (c) vs. (d)) and column-wise normalisations ((g) and (h)) do not change the correlation structure. The row-wise normalizations (c–f) change correlation structure and introduce the negative correlation.

the Pearson's correlations between two compositional components. To illustrate this problem, consider a simple, toy example of only two glycans representing a whole glycome of a person. Because of the constraint to the sum of a 100%, when the level of one glycan increases, the level of another must decrease. These two glycans are therefore negatively correlated.¹⁰ Such changes in correlation structure are shown in Fig. 3. In Table 1, we divide the six normalization methods considered here into two classes: row-wise (making samples comparable, Fig. 3(c)–(f)), and columnwise (making glycans comparable, Fig. 3(g) and (h)). Moreover, as can be seen in Fig. 3(a), glycans are highly correlated. To avoid overfitting and the multicollinearity problem, penalized regression can be considered. The effects of column-wise normalization such as centering and scaling will lead to a corresponding change in the scale of the coefficients and standard errors, but no change in the significance or interpretation. In contrast, if the compositional glycan data is used as covariates in regression analysis, the lasso regression should not be directly applied.¹¹

Another important issue to be addressed is measurement error in glycans. Compared to more abundant glycans, IgG glycans of low-abundance appear to be measured with up to 50% of measurement error, indicating an additive error (unpublished data). In gene expression data, where measurement error is approximately constant over a range of intensity levels near zero, it appears to be proportional to intensity level at large intensity levels,^{13,14} which might imply multiplicative error. Since the specific measurement error structure in the real data

Table 1	Normalization	methods i	nvestigated.	For	details	cf.	Section 2.1	
---------	---------------	-----------	--------------	-----	---------	-----	-------------	--

Normalization	Abbreviation	Description
Total area Log-transform of TA	TA logTA	Each glycan peak is divided by total abundance per subject, resulting compositional data. To achieve less-skewed distribution. When centering is applied to each sample, it is equivalent to the centred log-ratio (CLR) transformation. ^{a}
Reference peak ^b Median quotient	RP MQ	Each glycan peak is divided by the most abundant glycan peak per subject. To remove the bias due to the relative abundance of glycan intensities.
Median scaling Multivariate quantile normalization	MS MQN	Each glycan peak is subtracted by its median and divided by the interquartile range (IQR). Column-wise adaptation of quantile normalization in gene expression data.
	Total area Log-transform of TA Reference peak ^b Median quotient Median scaling Multivariate quantile	Total areaTALog-transform of TAlogTAReference peakbRPMedian quotientMQMedian scalingMSMultivariate quantileMQN

^{*a*} Aitchison¹² introduced transformations based on ratios: the additive log-ratio transformation (ALR) and the centred log-ratio transformation (CLR). ^{*b*} By taking the logarithm of RP, the additive log-ratio (ALR) transformation is obtained.

is not well studied, we consider three models: additive, multiplicative, and two-component measurement error in glycan measurements, the last containing both additive and multiplicative error components. We study the effects caused by measurement error in our simulation studies. Given that the real correlation structure between glycans is not known, to assess the influence of different normalizations on discovery of glycan biomarkers we simulated the data to mimic the real data and simulated association with an outcome. In short, we first generate the glycans that mimic the correlation structure of real glycan data, namely the log-transformed glycan measurements from the Orkney Complex Disease Study (ORCADES).¹⁵ Next, outcome variables are generated assuming that different sets of glycan combinations are associated with the outcome. In addition, based on different error models the corresponding error-contaminated datasets are generated. For each of simulated glycan datasets (with or without error) six different normalization methods are applied, and variable selection is employed. Finally, the impact of normalization on the performance of variable selection is assessed via extensive simulations reflecting various scenarios as described in Section 3.

The structure of the paper is as follows. In the next section, a detailed description of the considered normalization methods is given, followed by discussion on measurement error in glycomics data. In Section 3 we present our simulation study and evaluate the robustness and efficiency of the normalization methods regarding variable selection. Next, the analysis of glycan measurements from the ORCADES study¹⁵ is considered in Section 4, where glycan variable selection is performed with age as an outcome. Finally, in the last section we give some insights and recommendations based on the conducted simulation study.

2. Methods

2.1. Normalization methods

Let us first introduce some notation. Matrices are represented with bold upper case (\mathbf{X}) and column vectors as bold lower case (\mathbf{x}) letters. Let an $n \times p$ matrix $\mathbf{X} = (x_{ij})$, where i = 1, ..., nrepresents samples and j = 1, ..., p glycan variables of the cleaned raw data. Following the order presented in Table 1, the total area normalization (TA) can be written as follows:

$$\mathrm{TA}(x_{ij}) = x_{ij} / \sum_{j=1}^{p} x_{ij}$$

From this formula it is obvious that TA introduces constraint that $\sum_{j=1}^{p} TA(x_{ij}) = 1$. TA does not entirely correct for highly skewed distribution of glycans, and can add additional skewing to glycan intensity distributions. Therefore, the TA-normalized data TA(x_{ij}) is often log-transformed

$$\log TA(x_{ij}) = \log(TA(x_{ij}))$$

In the compositional data analysis literature further centring of logTA results in the centred log-ratio transformation.¹²

Denoting x_s the column vector of the most abundant glycan peak across the samples, the Reference Peak Normalization (RP) can then be written as

$$\operatorname{RP}(x_{ij}) = x_{ij}/x_{is}.$$

RP can generate a very small variance, and additional standardization may be needed.^{3,16} The drawbacks of RP are: one of the glycan chosen as the reference glycan x_s will not be included for the further analysis, and the choice of the reference glycans is highly subjective. Median quotient (MQ) is a modified version of Probabilistic Quotient Normalization (PQN).¹⁷ This method is based on the median fold change of all peak intensities with respect to a reference spectrum, or most commonly the median of the analysed data. PQN assumes that biologically interesting concentration changes influence only parts of the spectrum, while dilution effects will affect all signals in the spectrum.⁶ Assuming similar behaviour for the UPLC glycomics data, PQN can be adapted to suite glycomics data. First, to derive reference glycans, a median of each glycan vector x_i is calculated: median (x_i) , for $j = 1, \dots, p$. Next, for all glycan values x_{ij} the quotient of x_{ii} and the appropriate reference glycan is derived: $x_{ii}^{q} = x_{ii}$ median(x_i). Then for each sample *i*, the median of all quotients, x_i^{mq} = median(x_{ii}^{q}), is calculated. Finally, all glycans are divided by the median quotient.

$$MQ(x_{ij}) = x_{ij}^{q}/median(x_i^{mq}).$$

The next two methods involve column-wise normalization. Considering a highly right-skewed distribution, a log-transformation is carried out prior to column-wise normalization. For convenience, we use the same notation x_{ij} for the abundance on the log scale of the *j*th glycan in the *i*th sample for i = 1, ..., nand $j = 1, \dots, p$. Median Scaling (MS) stands for the nonparametric version of the standardization (centring and scaling), which is sometimes simply called scaling.¹⁸ In the parametric setting, the procedure is to subtract the mean from each glycan and to divide by the standard deviation, resulting in zero mean and a standard deviation of one. This often leads to the inflation of small values. The measurement error being sometimes relatively large for small values, this can enlarge undesirable effects on further analysis. Hence, we chose to study a more robust version: to subtract the median from each glycan and divide by the interquartile range (IQR), *i.e.* for *j*th glycan

$$MS(x_{ij}) = \{x_{ij} - median(x_i)\}/IQR(x_i)\}$$

Quantile normalization (QN) is a row-wise normalization proposed by Bolstad *et al.*¹⁹ It was derived for gene-expression data and the justification for it comes from the idea that only a handful of genes in most studies should be differentially expressed between samples and therefore the distribution of intensities should be approximately the same. Any discrepancies between the intensity distributions are due to measurements errors. We adapt QN to glycan data to achieve the same distribution of glycan intensities across all glycans, which is column-wise normalization. If two glycan intensities share the same distribution, all quantiles will be identical and, hence, align along the diagonal. This concept is extended to *p* dimensions in our case, and in fact can be interpreted as multivariate version of rankbased inverse normal transformation, transformation often used in a genome-wide association study (GWAS) setting. To make distinction clear we call this method Multivariate Quantile normalization (MQN). Thus, if all *p* glycan vectors have the same distribution, then plotting the quantiles in *p* dimensions gives a straight line along the line given by the unit vector $(1/\sqrt{p}, \ldots, 1/\sqrt{p})$. For further computational details we refer to ref. 19.

2.2. Normalization can change correlation structure

Let *X* denote an $n \times p$ matrix containing glycan measurements for *n* samples and *p* glycans. Without loss of generality we assume that *X* has a multivariate normal distribution with mean μ and covariance matrix Σ . The transformation performed by TA on a row (sample) is given by

$$(\tilde{x}_1,\ldots,\tilde{x}_p)=(x_1,\ldots,x_p)/(x_1+\cdots+x_p),$$

introducing the constraint that $\sum_{j} \tilde{x}_{j} = 1$. This, unfortunately, leads to the problem of losing the possibility to interpret the correlation coefficients between the original components, commonly referred to as the negative bias problem.¹⁰ This means that for a *p*-part composition $(\tilde{x}_{1}, \dots, \tilde{x}_{p})$ we have

$$\operatorname{Cov}(\tilde{\boldsymbol{x}}_1, \, \tilde{\boldsymbol{x}}_1 + \cdots + \, \boldsymbol{x}_p) = 0.$$

Consequently,

$$\operatorname{Cov}(\tilde{\boldsymbol{x}}_1, \tilde{\boldsymbol{x}}_2) + \cdots + \operatorname{Cov}(\tilde{\boldsymbol{x}}_1, \tilde{\boldsymbol{x}}_p) = -\operatorname{Var}(\tilde{\boldsymbol{x}}_1).$$

Thus at least one of the covariances on the left must be negative, and consequently, there must be at least one negative element in each row of the raw covariance matrix.²⁰ Fig. 3(c)-(f) show the different patterns of correlation matrix caused by the different row-wise normalization methods.

2.3. Measurement error models

Standard regression models assume that the covariates have been measured precisely, or observed without error. In contrast, the so-called errors-in-variables models or measurement error models are regression models that account for measurement errors in the independent variables (*i.e.* covariates, predictors).²¹ We use measurement error models to generate glycomics datasets that contain measurement errors for our simulation study.

Assuming X has a multivariate normal distribution with mean μ and covariance matrix Σ , we consider a regression of a response Y on a predictor or covariate X. Instead of observing X, we observe W: *i.e.*, error-free data (Y, X) versus the error-contaminated data (Y, W). First, for additive error we have $W_A = X + U_1$, where U_1 is additive error independent of X. U_1 is normally distributed and has mean zero and covariance matrix Σ_{U_1} . For simple linear regression the effect of having additive measurement error in a covariate is said to be an underestimate of the coefficient, known as the attenuation bias. The effects can vary depending on simple or multiple regression, and whether a covariate measured with error is univariate or multivariate. For our simulation study, we consider

a diagonal matrix for uncorrelated error as well as a full matrix for correlated errors. For the multiplicative measurement error, we have $W_{\rm M} = XU_2$, where U_2 is multiplicative error. It indicates that the largest observed values are very far from the true values. If $U \sim \mathcal{N}(0, \Sigma_U)$ and $U_{2,j} = \exp(U_j)$, for j = 1, ..., p, then U_2 has a multivariate log-normal distribution with mean zero and covariance matrix Σ_U . Lastly, the two-component model or Rocke–Lorenzato model^{13,22} containing both additive and multiplicative error is as follows: $W_{\rm MA} = XU_2 + U_1$, where U_1 and U_2 are independent errors. In the univariate case, $w = x\sigma_2^2 + \sigma_1^2$, and this implies $\operatorname{Var}(w|x) = x^2\sigma_2^2 + \sigma_1^2$. For sufficiently small values of x, $\operatorname{Var}(w|x)$ is similar to σ_2^2 .²¹ This behaviour in the multivariate case will be studied using simulations.

2.4. Variable selection and prediction

We consider a multiple linear regression model with *n* observations on a dependent variable $\mathbf{y} = (y_1, \dots, y_n)^T$ and *p* glycans as predictors (or covariates). Let $\mathbf{1}_n$ denote a vector of ones of length *n*, and *I* an identity matrix. In matrix notation the linear regression model can be written as:

$$y = X\beta + \varepsilon, \tag{1}$$

where $y = (y_1, ..., y_n)^T$, $X = (1_n, x_1, x_2, ..., x_p)$ is the $n \times (p + 1)$ matrix of standardized covariates, $\boldsymbol{\beta} = (\beta_0, \beta_1, \dots, \beta_p)^T$ and $\boldsymbol{\varepsilon} \sim \mathcal{N}(0, \sigma_{\varepsilon}^{2}\boldsymbol{I})$. Often when we are given a large number of covariates and due to different reasons (like the high cost of measuring all these covariates or inability to interpret results with many covariates), we would like to obtain a reduced set of covariates including only those that are necessary to obtain a "good enough" model. Also, we may have some domain knowledge telling us that only a few predictors should indeed be important for an outcome and therefore our "good enough" model is the best model. In other words, it is frequently assumed that most regression coefficients β_i are zero. Variable selection aims to identify all important variables whose regression coefficients are not zero and to provide effective estimates of those coefficients. These variable selection features can lead to finding smaller groups of variables with good prediction accuracy. A potentially simple and effective tool for variable selection is the stepwise selection. However, it has severe problems in the presence of collinearity.

Among many methods, to achieve good prediction, to avoid overfitting, and to obtain an interpretable model, we consider the Least Absolute Shrinkage and Selection Operator (lasso) proposed by Tibshirani.²³ This method considers both continuous shrinkage and variable selection. The lasso is a penalized least squares procedure that minimizes RSS = $(\tilde{y} - X\beta)^T(\tilde{y} - X\beta)$ where $\tilde{y} = y - y \mathbf{1}_n$, subject to the non-differentiable constraint expressed in terms of the L_1 norm. The lasso estimator is given by

$$\hat{\boldsymbol{\beta}} = \arg\min_{\boldsymbol{\beta}} (\tilde{\boldsymbol{y}} - \boldsymbol{X}\boldsymbol{\beta})^{\mathrm{T}} (\tilde{\boldsymbol{y}} - \boldsymbol{X}\boldsymbol{\beta}) + \lambda \sum_{j=1}^{p} |\beta_{j}|$$
(2)

where $\lambda \ge 0$ is a tuning parameter. The optimal λ can be selected by *k*-fold cross-validation, which gives minimum mean crossvalidated error, with common choices of *k* equal to 5 and 10. To assess how the results of different scenarios will generalize to external datasets, we investigate performance of predictive model through estimating accuracy of a predictive model applied to a new independent data. We therefore first build the model (or perform variable selection) using a training and test dataset, and then validate the model composed of the selected variables using an external validation dataset. To summarize the results, we report the numbers of correctly and incorrectly selected variables, and we quantify the prediction error,²⁴ defined by squared root of the average error in the prediction of **y** given **X** for future cases not used in the construction of a prediction equation. Formally, if $\hat{\mu}(\mathbf{X})$ is the predicted values constructed using the present data, the prediction error can be written as

$$PE(\hat{\mu}) = \sqrt{E[\mathbf{y} - \hat{\mu}(\mathbf{X})]^2},$$
(3)

where the expectation is taken only with respect to the new observation.

3. Simulation study

3.1. Simulation schemes

(i) Generate the glycan data *X* based on the correlation structure of real data. We simulate 1000 datasets consisting of 2n (n = 1000, for *n* model building set and *n* validation set) observations. The *p* glycans (p = 24) are drawn from multivariate normal distribution with mean μ and covariance matrix Σ . Details such as μ and Σ of real data and *X* are shown in Table S1 (ESI†). To mimic the skewed clean data exp(*X*) is used.

(ii) Generate the error-contaminated glycan data W. We simulate 1000 datasets consisting of 2n observations and p glycans generated with three different error models – additive, multiplicative, two-component. The parameters of the covariance matrix Σ are shown in Table 2. The diagonal elements are denoted as $\sigma_{ii} = \sigma_i^2$, and the off-diagonal elements as $\sigma_{ij} (i \neq j)$. We consider both correlated and uncorrelated covariance matrices.

(iii) Simulation of trait (y). Based on linear regression $y = X\beta + \varepsilon$ (eqn (1)) with $\varepsilon_i \sim \mathcal{N}(0, 1)$, and the coefficients β were set as follows:

• 3 coefficients fixed: $\beta_{j \in \{1,2,10\}} = (1,0.5,2)^{T}$ and all other $\beta_{i\{1,2,10\}} = 0$.

• 6 coefficients fixed: $\beta_{j \in \{1,2,10,15,16,17\}} = c(1,0.5,2,3,0.5,1)^{T}$ and all others are set to zero.

The descriptives of *y* are given in Table S1 (ESI[†]).

Table 2 Parameters in covariance matrix Σ										
		Additiv	/e	Multiplicative						
Error type	σ_{ii}	σ_{ij}	σ_{ii}	σ_{ij}						
Correlated	E1 E2	1/4 1	1/8 0.5	$\begin{array}{c} 0.1 \\ 0.01 \end{array}$	0.05 0.005					
Uncorrelated	E1 _{un} E2 _{un}	1/4 1	0 0	$\begin{array}{c} 0.1 \\ 0.01 \end{array}$	0 0					

(iv) Six normalization methods. For each of the error-free and -contaminated glycan datasets – glycan data generated from the steps (i) and (ii) – the TA, logTA, RP, MS, MQ, or MQN transformation is applied.

(v) Regression. Using *n* training sets we apply lasso penalized regression for variable selection and prediction. The effect estimates $\hat{\beta}$ are compared to the true β .

(vi) Prediction. Using *n* (independent) validation or test sets, $\hat{\beta}$ estimates from the variable selection (step v) are plugged in the model, and the fitted outcome \hat{y} are compared to the true *y*.

(vii) To assess the performance of variable selection, the average number of the correctly and incorrectly (falsely) selected variables is computed. For prediction performance the root mean squared prediction error (eqn (3)) is computed.

3.2. Distribution of error-contaminated glycans

We first show how the different error models change the distribution of simulated glycan data. Fig. 4 shows the glycan distributions of such simulated data with and without the correlated error E1 in Table 2. The first row depicts the distribution of the highly skewed cleaned raw data, and that of the log-transformed data, which induces relative symmetry of glycan distributions, still having the same correlation structure. The second row, the left figure shows the error-free simulated data, SIMdata, based on the real log-transformed data. The rest depicts the distribution of the simulated data under additive, multiplicative, and two-component error model. While data with additive error showed similar distribution and correlation patterns, introducing multiplicative error in glycans makes the distribution skewed. Moreover, multiplicative error dominates additive error.

3.3. Results of variable selection and prediction of multiple glycan predictors

Tables 3 and 4 show the results based on correlated errors under E1 and E2, respectively. The results of each table are averaged across 1000 simulations: for six normalization methods, two sets of fixed coefficients (3 and 6 β s), and four different error models (data without additional measurement error, and with additive, multiplicative, and two-component). For evaluation of the performance of normalization methods we considered (i) the number of the correctly selected variables, namely 3 or 6, (ii) the number of falsely selected variables (should be zero), and (iii) prediction error as defined in (3).

The first row of each error model in Table 3, *SIMdata*, serves as a reference point and can be interpreted as the best achievable results under the correct model. Even when glycans were simulated without additional measurement error, the number of the falsely selected variables was non-zero: 4.46 for 3 fixed coefficients, and 5.12 for 6 fixed coefficients in average. When additive error in the data, the number of the falsely selected (13.57 and 15.31, respectively) becomes large, indicating a poor performance of variable selection. When multiplicative error was introduced the number of both correctly and incorrectly selected variables decreased and prediction error increased. The results of two-component error were close to those of




Fig. 4 Distribution of glycans with correlated error. The green and yellow color depicts the measured and simulated data, respectively. (i) The first row, colored green, depicts the cleaned and its log-transformed data: the extreme range of abundance and the highly right skewed distribution of cleaned data can be dealt with the log-transformation of the data. (ii) The second row shows error-free simulated data based on the log-transformed cleaned data, and the error-contaminated data with additive error (E1), which showed similar distribution patterns. (iii) The last row multiplicative and two-component error under E1. Introducing multiplicative error in glycans made the distribution skewed, and the range of abundances larger. The similarity of two distribution patterns indicates that multiplicative error dominates additive error.

multiplicative error, which indicates that in this parameter setting multiplicative error dominates additive one. Among row-wise normalization methods, TA and logTA perform poorly for variable selection when multiplicative error was involved. For multiplicative and two-component error the performance of all normalization methods was comparable; variable selection and prediction became exceedingly difficult. Overall, the column-wise normalizations outperformed the row-wise normalizations. Moreover, the results from two column-wise normalization, MS and MQN, were similar to *SIMdata* under all error models of Table 2.

Based on the error model E2 (Table 4), in which multiplicative errors have very small variances compared to additive ones, the number of incorrectly selected variables for the benchmark, *SIMdata*, was very large across all error types, leading to a poor variable selection performance. Prediction error seemed more controllable than under E1.

Fig. 5 highlights the prediction performance. Since the results of the models including 3 and 6 β 's were similar, only the performance based on the models with 6 β 's under E1 and E2 is shown. In case of uncorrelated error, compared to Table 3, the effects of the error in glycans became more marked (data not shown). Comparison of the correlated and uncorrelated error based on 6 β s in the model and the two-component error model is depicted in Fig. S1 (ESI†). The correlated error caused a poorer performance in variable selection.

To summarize the simulation results, even without additional measurement error the row-wise normalization appeared to perform poorly based on simulated glycan data, in terms of false positives and accurate prediction. Adding error caused perturbation of correlation structure, and especially introducing multiplicative error resulted in smaller number of variables in the model (less correctly- and incorrectly selected variables) and larger prediction error.

Table 3Results of simulation study. Variable selection and prediction ofmultiple glycans based on the correlated error model E1 in Table 2 using1000 replicates

		3 beta's ^a			6 beta's ¹)	
Error model	Nr correct ^c	Nr false ^d	PE^{e}	Nr correct	Nr false	PE	
Error-free	SIMdata ^f	3.00	4.46	1.00	5.94	5.12	1.0
	MS	3.00	4.47	1.00	5.94	5.10	1.0
	MQN	3.00	4.52	1.00	5.94	5.29	1.0
	TA	2.83	17.96	1.88	5.18	15.7	3.7
	logTA	2.97	19.86	1.83	5.75	17.2	3.62
	RP	1.83	13.21	2.33	5.73	17.13	3.6
	MQ	1.88	12.99	2.33	5.71	16.19	3.62
Additive	SIMdata	3.00	13.57	1.50	5.38	15.31	2.69
	MS	3.00	13.63	1.50	5.37	15.32	2.6
	MQN	3.00	13.58	1.50	5.37	15.29	2.7
	TA	2.42	16.46	2.18	4.91	14.63	4.5
	logTA	2.61	17.19	2.16	5.24	15.47	4.5
	RP	2.61	17.25	2.16	5.18	15.82	4.5
	MQ	2.70	16.98	2.16	5.44	15.56	4.5
Multiplicative	SIMdata	2.12	8.90	2.29	3.03	8.50	4.9
-	MS	2.14	8.89	2.29	3.02	8.46	4.9
	MQN	2.12	8.76	2.29	3.03	8.46	4.9
	TA	0.29	1.68	2.36	0.45	1.32	5.0
	logTA	0.61	6.50	2.35	1.62	6.15	5.0
	RP	0.64	4.27	2.36	1.54	4.36	5.0
	MQ	0.54	4.14	2.36	1.46	4.09	5.0
Two-	SIMdata	2.06	9.07	2.30	3.01	8.30	4.8
component	MS	2.06	9.09	2.30	3.02	8.40	4.8
	MQN	2.07	9.13	2.30	3.00	8.29	4.8
	TA	0.23	1.66	2.36	0.49	1.38	5.0
	logTA	0.63	6.68	2.35	1.63	5.93	5.0
	RP	0.64	4.37	2.36	1.59	4.19	5.0
	MQ	0.55	4.26		1.57	4.27	5.0

Table 4Results of simulation study. Variable selection and prediction ofmultiple glycans based on the error model E2 in Table 2 using 1000replicates

		3 beta's ^a		6 beta's ^b			
Error model	Nr correct ^c	Nr false ^d	PE^{e}	Nr correct	Nr false	PE	
Additive	Simdata ^f	f 2.74	13.91	1.92	5.26	15.02	3.87
	TA	1.82	14.00	2.31	3.82	11.57	4.93
	logTA	2.26	15.68	2.29	4.62	13.86	4.86
	RP	2.34	15.81	2.29	4.84	4.94	4.85
	MQ	2.45	15.48	2.29	5.01	14.77	4.85
Multiplicative	Simdata	2.65	16.06	1.87	5.07	15.05	3.83
	TA	1.83	13.80	2.32	4.00	11.75	4.94
	logTA	2.00	16.10	2.28	4.51	14.63	4.84
	RP	2.22	15.50	2.29	4.65	14.01	4.86
	MQ	2.30	15.28	2.29	4.96	13.96	4.86
Two-	Simdata	2.67	12.25	2.10	4.32	10.99	4.37
component	TA	1.08	8.77	2.35	2.49	7.58	5.01
	logTA	1.66	13.25	2.33	3.64	11.64	4.94
	RP	1.81	12.35	2.10	4.05	11.87	4.96
	MQ	1.84	12.24	2.10	4.36	12.25	4.96

^{*a*} The glycans 1, 2, and 10 were assumed to have non-zero effects, and all other 21 glycans no effect. ^{*b*} The glycans 1, 2, 10, 15, 16 and 17 were assumed to have non-zero effects, and all other 18 glycans no effect. ^{*c*} The average number of correctly selected glycans. ^{*d*} The average number of falsely selected glycans, which should be close to zero. ^{*e*} The root mean squared error of prediction with respect to the new observations. ^{*f*} The rows in italics show the results of simulated data without additional error in glycans, which can be interpreted as the best achievable results under the correct models.

^{*a*} The glycans 1, 2, and 10 were assumed to have non-zero effects, and all other 21 glycans no effect. ^{*b*} The glycans 1, 2, 10, 15, 16 and 17 were assumed to have non-zero effects, and all other 18 glycans no effect. ^{*c*} The average number of correctly selected glycans. ^{*d*} The average number of falsely selected glycans, which should be close to zero. ^{*e*} The root mean squared error of prediction with respect to the new observations. ^{*f*} The rows in italics show the results of simulated data without additional error in glycans, which can be interpreted as the best achievable results under the correct models.

4. Data application

Glycans have been previously reported as biomarkers of both chronological and biological ages.²⁻⁴ These results were obtained using single-point analysis where the association between each glycan and ageing outcome was studied one at a time. Here we aim to detect multiple biomarkers associated with ageing, all in one go. Considering high correlation shown among glycan variables, to avoid overfitting and to obtain an interpretable model, the lasso regression²³ in Section 2.4 is applied to the data from Scottish island of Orkney.¹⁵

Glycan traits bound to immunoglobulin G (IgG) (Fig. 1) were measured by ultra-performance liquid chromatography (UPLC) in 2035 individuals from the ORCADES study, as described in Kristic *et al.*² As can be seen in Fig. 1, 24 different glycan peaks are quantified using UPLC, with each glycan peak containing one or more glycan structures. Abundance of individual glycan structures in every glycan peak can be found in Pucic, *et al.*²⁵

Participants were men and women (797; 1238) aged between 17 and 100 years (median age, 54). To explore effects of different normalization on biomarker selection of age, the glycan abundance was transformed using six normalization methods shown in Table 1, and additional logRP (log-transformation of RP). To remove strong batch effects in the glycomics data, following different normalization, we performed batch correction using empirical Bayes method²⁶ as implemented in the ComBat function of sva package for R.²⁷ To determine the 'best' model, applying the lasso requires selecting a value for the tuning parameter λ in eqn (2). For this training and testing of the model, ten-fold cross-validation was applied to the lasso fits in two third of the dataset. Then, the selected model was re-fitted for predicting age to the remaining onethird of the data (validation set). For comparison of the performance of each normalization, variable selection (in terms of non-zero coefficients) and accuracy in prediction are presented in Table 5.

Here, the results of variable selection is presented as (boldfaced) non-zero coefficients (effect size). For example, if you use TA normalization, 3 glycans (GP6, GP10, and GP14) will be selected as potential biomarkers with prediction error 10.52. In contrast, the smallest prediction error (10.36) is obtained using MQN, which selects 5 glycans (GP2, GP6, GP10, GP14, and GP24). GP6 and GP14 are the stable associated glycans, which are selected using every normalization methods. RP and log RP selected 6 and 3 glycans, respectively. However, the absolute effect size of the 'stable' glycans (GP6 and GP14) is *ca.* 10-fold




Fig. 5 Comparison of prediction performance based on prediction error; the smaller error, the better performance. SIMdata in the right shows the prediction error without introducing error. (i) Under the error model E1: in the case of perturbation of additive error, the column-wise normalized (MS and MQN) data performed similarly well. When multiplicative error is present (multiplicative or two-components), multiplicative error dominates. (ii) The lower row shows the error model E2, which has smaller multiplicative error than E1. The results show similar prediction error patterns as in (i). Throughout all scenarios, the column-wise normalization methods outperform the row-wise ones; *i.e.*, smaller prediction error using MS and MQN.

greater than that of other normalizations, indicating biased results. Less robust (with smaller effect size), but evidence of association of GP2, GP10, and GP24, can be found using the majority of the normalization methods (represented by the bold-faced glycans in the first column).

To summarize, with regard to the accuracy of prediction, MQN showed the smallest prediction error, followed by logTA and MS. In terms of variable selection, MQ selected the largest number of the variables, thereby failing to provide sparse model. In particular, the strong effect size of GP14 appears to influence the selection of neighbouring GP13 and GP15. The other row-wise normalization, TA and RP (including logRP), results in seemingly 'out-of-range' values, which lacks model interpretability. Based on the magnitude of the effect sizes as well as variable selection, logTA (row-wise) and MS and MQN (both column-wise) seem to agree on the selected glycans.

5. Discussion

It is often claimed that glycans are by their nature compositions, and that percentage of glycan species in the whole is biologically relevant information.²⁸ To dispute such claims is not of our interest; our intention is to increase the awareness of spurious correlations caused by row-wise normalization. In this work, we did not try to disentangle the true correlation structure in view of biochemical pathways, but rather demonstrated that choosing one normalization method can cause several potential issues and problems for downstream analysis. In particular, we focused here on variable selection by implementing standard statistical learning. When sample-wise differences are non-ignorable, more investigation for the choice of normalization method is needed. One of the challenges is how to generate or simulate such data to study statistical properties. Table 5 The glycan biomarker selection: the bold-faced glycans with non-zero coefficients selected by different normalization methods can be seen as the robust glycan-age biomarkers

	Row-wise	Column-wise					
			RP	$\log RP^{a}$	MQ		
Glycan	TA	logTA	Effect sizes (c	Effect sizes (coefficients)		MS	MQN
GP1	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP2	0.00	1.36	32.53	12.27	2.26	2.28	2.8
GP3	0.00	0.00	0.00	0.00	0.55	0.00	0.0
GP4	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP5	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP6	2.06	12.05	123.14	129.56	9.97	13.33	14.1
GP7	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP8	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP9	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP10	0.63	2.55	90.74	0.00	8.14	0.00	1.4
GP11	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP12	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP13	0.00	0.00	-58.53	0.00	-7.38	0.00	0.0
GP14	-1.72	-20.65	-259.85	-212.61	-14.76	-16.56	-20.0
GP15	0.00	0.00	0.00	0.00	-2.76	0.00	0.0
GP16	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP17	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP18	0.00	0.00	0.00	0.00	-0.63	0.00	0.0
GP19	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP20	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP21	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP22	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP23	0.00	0.00	0.00	0.00	0.00	0.00	0.0
GP24	0.00	0.48	9.39	0.00	0.00	1.41	2.1
Variable selection ^b	3	5	6	3	8	4	5
Prediction error ^c	10.52	10.40	10.45	10.83	10.46	10.40	10.3

^{*a*} Log-transformation of RP is included, which is equivalent to the ALR transformation.^{12 *b*} The number of non-zero coefficients (selected variables). ^{*c*} As defined in eqn (3). The smaller, the better performance.

Moreover, platform differences between measurement technologies such as ultra-performance liquid chromatography (UPLC) or nano liquid chromatography-electrospray ionization-mass spectrometry (nanoLC-ESI-MS) cannot be ignored. At this moment we do not have sufficient knowledge to deal with these issues.

In this work we also addressed the effect of possible measurement error present in glycans. In general, introducing error caused decrease in the strength of correlations, and in particular multiplicative error produced more perturbation in correlation structure. In case of two-component error, the tendency of decreasing correlation was more pronounced. Moreover, even with very small multiplicative error, multiplicative error dominated additive one. Our simulation study clearly indicates that understanding measurement error structure is crucial, not only to extract real signals from noise-ridden data, but also to improve accuracy and efficiency of variable selection and prediction for finding glycan biomarkers. In statistics, measurement error models or errors-in-variables models are regression models that account for measurement errors in independent variables.21 Here, given that the real-life data measurement error is not well studied, we did not consider how to correct for the attenuation bias in multivariate errors-in-variables regression, but applied measurement error model to generate datasets contaminated with various types of error. We also included here an arbitrary correlated error structure, assuming that the highly correlated glycan data will have correlated errors.

Nevertheless, replicates are more and more used in quantification of glycans and it will soon be possible to estimate the correlated measurement error for glycan data, which will greatly improve data pre-processing of glycan measurements.

Via simulation we have shown the row-wise normalization methods can have deleterious effects on variable selection based on multiple regression with the glycans covariates. When applied to the real data, two column-wise (MS and MQN) and logTA gave similar results in terms of variable selection, prediction, and the magnitude of effect estimates. For argument's sake, assuming the glycomics data resembles the microbiome count data and is compositional, what are the possibilities to obtain valid results? Although compositional data are proven difficult to handle statistically - the covariance matrix is not positive-semi-definite (or singular) and the level of the variance depends on the mean of the distribution - statistical methods for such data have been developed. For principal component analysis, Aitchison proposed a log linear contrast form to deal with compositional data,²⁹ Regarding the variable selection problem, Lin et al.³⁰ addressed this in high-dimensional regression with compositional covariates, motivated by research problems arising in the analysis of gut microbiome and metagenomic data. They considered the linear log-contrast model of Aitchison and Bacon-Shone.³¹ Whether any of these approaches would be beneficial for glycomics data analysis is yet to be determined. In particular, for network analysis where the analysis is based

Molecular Omics

on correlation structure, it is not at all clear how to perform analysis based on the TA normalized data.³²

With regard to biomarker discovery, it might be a better strategy to analyse glycans jointly. New groups of a few glycans, called derived traits, can be constructed, which represent groups of glycan structures that have similar structural and chemical properties. Up until now, these derived traits often exhibited stronger associations with studied outcome. Alternatively, we investigated here well-established variable selection and prediction method to discover multiple glycans that might be jointly responsible for association with disease trait. As shown in application to the real data (Table 5), the glycan biomarkers with large effect were selected, regardless which method was applied. To identify glycans with smaller effect and to avoid false positive and biased results, a few normalization methods (such as logTA, MS and MQN) can be employed to check the robustness of variable selection. Our simulation study clearly demonstrated that incorrect pre-processing steps might hamper discovery of reliable biomarkers. Another nonignorable issue emerged from simulation study was the large amount of false positives (or falsely selected), due to the highly correlated nature of glycan measurements. In various scenarios many false positives were found, and therefore the task of variable selection failed. Hence, robustness of glycan biomarkers is of utmost importance for further investigation.

Regardless of the correlation structure or glycan measurement technology used, row-wise normalizations introduce spurious correlations and can therefore have an effect on downstream statistical analyses. The specific effects of other normalization methods on biomarker discovery not assessed in this paper should be studied before being implemented in measurement technology specific preprocessing procedures.

6. Conclusion

Modern high-throughput glycomics data measured by UPLC typically shows (i) that the between-subject differences in total abundance are very large, and (ii) that the glycans are highly correlated. Therefore, glycomics abundances should be normalized to comparable scales, and to avoid overfitting special care is needed for jointly selecting multiple biomarkers. Here, we assessed the impact of various normalization methods on glycomics biomarker selection using lasso regression. Through an extensive simulation study, we demonstrated that the widely used row-wise total area (TA) normalization method performs poorly compared to the column-wise normalization methods - glycans were falsely selected (false positives) and the prediction error was large. The column-wise normalization methods, such as MS and MQN, not only outperformed the row-wise methods but also have an advantage of preserving the correlation structure. Measurements error in glycan abundances, moreover, caused perturbation of correlation structure and diluted the signals in the data, which led to decreased accuracy in variable selection. Further application to the real data problem of glycan biomarker selection for biological

ageing, confirmed these findings. To identify glycans with smaller association effects and to avoid false positives and biased results, we recommend to apply several normalization methods, such as logTA, MS and MQN, and report the association results that are detected by majority of them. This procedure will assist in identifying robust and reproducible glycan biomarkers.

Conflicts of interest

Gordan Lauc is a founder and owner of the Genos Glycoscience Research Laboratory, a private research organization that specializes in high-throughput glycomic analysis and has several patents in this field. The other authors declare that they have no competing interests.

Acknowledgements

The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7-Health-F5-2012) under grant agreement number 305280 (MIMOmics), and from the European Union's Horizon 2020 research and innovation programme IMforFUTURE under H2020-MSCA-ITN grant agreement number 721815. Authors thank to Gordan Lauc and James F. Wilson for providing ORCADES data that were the basis for simulation study and prediction of age. The work of LK was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to J. F. W., the MRC Human Genetics Unit quinquennial programme "QTL in Health and Disease", Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).

References

- 1 D. Walt, *Transforming Glycoscience: A roadmap for the future*, The National Academic Press, Washington DC, 2012.
- J. Krištić, F. Vučković, C. Menni, L. Klarić, T. Keser, I. Beceheli, M. Pučić-Baković, M. Novokmet, M. Mangino, K. Thaqi, P. Rudan, N. Novokmet, J. Sarac, S. Missoni, I. Kolčić, O. Polašek, I. Rudan, H. Campbell, C. Hayward, Y. Aulchenko, A. Valdes, J. F. Wilson, O. Gornik, D. Primorac, V. Zoldoš, T. Spector and G. Lauc, Glycans are a novel biomarker of chronological and biological ages, *J. Gerontol.*, *Ser. A*, 2014, **69**(7), 779–789, DOI: 10.1093/gerona/glt190.
- 3 L. R. Ruhaak, H.-W. Uh, M. Beekman, C. H. Hokke, R. G. J. Westendorp, J. Houwing-Duistermaat, M. Wuhrer, A. M. Deelder and P. E. Slagboom, Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health, *J. Proteome Res.*, 2011, **10**(4), 1667–1674, DOI: 10.1021/pr1009959.
- 4 V. Vanhooren, X.-E. Liu, C. Franceschi, C.-F. Gao, C. Libert, R. Contreras and C. Chen, N-glycan profiles as tools in

diagnosis of hepatocellular carcinoma and prediction of healthy human ageing, *Mech. Ageing Dev.*, 2009, **130**(1–2), 92–97, DOI: 10.1016/j.mad.2008.11.008.

- 5 R. Goodacre, D. Broadhurst, A. K. Smilde, B. S. Kristal, J. D. Baker, R. Beger, C. Bessant, S. Connor, G. Capuani, A. Craig, T. Ebbels, D. B. Kell, C. Manetti, J. Newton, G. Paternostro, R. Somorjai, M. Sjostrom, J. Trygg and F. Wulfert, Proposed minimum reporting standards for data analysis in metabolomics, *Metabolomics*, 2007, 231–241.
- 6 S. M. Kohl, M. S. Klein, J. Hochrein, P. J. Oefner, R. Spang and W. Gronwald, State-of-the art data normalization methods improve NMR-based metabolomic analysis, *Metabolomics*, 2012, **8**(1), 146–160.
- 7 M.-A. Dillies, A. Rau, J. Aubert, C. Hennequet-Antier, M. Jeanmougin, N. Servant, C. Keime, G. Marot, D. Castel, J. Estelle, G. Guernec, B. Jagla, L. Jouneau, D. Laloë, C. Le Gall, B. Schaëffer, S. Le Crom, M. Guedj, F. Jaffrézic and FS Consortium, A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis, *Briefings Bioinf.*, 2013, 14(6), 671–683.
- 8 J. Atchison, The statistical analysis of compositional data (with Discussion), J. R. Stat. Soc. B, 1982, 44, 139–177.
- 9 V. Pawlowsky-Glahn, J. J. Egozcue and R. Tolosana-Delgado, Modelling and analysis of compositional data, John Wiley & Sons, Ltd., Hoboken, NJ, 2015, https://www.wiley.com/en-nl/Modeling+ and+Analysis+of+Compositional+Data-p-9781118443064.
- 10 K. Pearson, Mathematical contributions to the theory of evolution: on a form of spurious correlation which may arise when indices are used in the measurements of organs, *Proc. R. Soc. London*, 1897, **60**, 489–498.
- H. Li, Microbiome, Metagenomics, and High-Dimensional Compositional Data Analysis, *Annu. Rev. Stat. Appl.*, 2015, 2(1), 73–94, DOI: 10.1146/annurev-statistics-010814-020351.
- 12 J. Aitchison, *The statistical analysis of compositional data*, Blackburn Press, 2003.
- 13 D. M. Rocke and B. Durbin, A model for measurement error for gene expression arrays, *J. Comput. Biol.*, 2001, 8(6), 557–569, DOI: 10.1089/106652701753307485.
- 14 M. F. Van Batenburg, L. Coulier, F. van Eeuwijk, A. K. Smilde and J. A. Westerhuis, New figures of merit for comprehensive functional genomics data: the metabolomics case, *Anal. Chem.*, 2011, 83, 3267–3274.
- 15 R. McQuillan, A. L. Leutenegger, R. Abdel-Rahman, C. S. Franklin, M. Pericic, L. Barac-Lauc, N. Smolej-Narancic, B. Janicijevic, O. Polasek, A. Tenesa, A. K. MacLeod, S. M. Farrington, P. Rudan, C. Hayward, V. Vitart, I. Rudan, S. H. Wild, M. G. Dunlop, A. F. Wright, H. Campbell and J. F. Wilson, Runs of Homozygosity in European Populations, *Am. J. Hum. Genet.*, 2008, **83**(3), 359–372, DOI: 10.1016/j.ajhg.2008.08.007.
- 16 L. R. Ruhaak, H.-W. Uh, M. Beekman, C. A. M. Koeleman, C. H. Hokke, R. G. J. Westendorp, M. Wuhrer, J. J. Houwing-Duistermaat, P. E. Slagboom and A. M. Deelder, Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity, *PLoS One*, 2010, 5(9), e12566, DOI: 10.1371/journalpone0012566.

- 17 F. Dieterle, A. Ross, H. Schlotterbeck and G. Senn, Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures Application to 1H NMR metabolomics, *Anal. Chem.*, 2006, **78**, 4281–4290.
- 18 R. A. van den Berg, H. C. J. Hoefsloot, J. A. Westerhuis, A. K. Smilde and M. J. van der Werf, Centering, scaling, and transformations: improving the biological information content of metabolomics data, *BMC Genomics*, 2006, 7, 142.
- 19 B. M. Bolstad, Pre-processing DNA microarray data, *Fundamentals of data mining in genomics and proteomics*, Springer, 2007, pp. 51–78.
- 20 J. Aitchison, A concise guide to compositional data analysis, 1999.
- 21 R. J. Carroll, D. Ruppert, L. A. Stefanski and C. M. Crainiceanu, *Measurement Error in Nonlinear Models, A Modern Perspective*, Chapman and Hall/CRC, 2nd edn, 2006.
- 22 D. M. Rocke and S. Lorenzato, A two-Component model for measurement error in analytical chemistry, *Technometrics*, 1995, 37, 176–184.
- 23 R. Tibshirani, Regression shrinkage and selection *via* the lasso, *J. R. Stat. Soc. B*, 1996, **58**, 267–288.
- 24 J. Fan and R. Li, Variable Selection *via* Nonconcave Penalized Likelihood and its Oracle Properties, *J. Am. Stat. Assoc.*, 2001, 96(456), 1348–1360, DOI: 10.1198/016214501753382273.
- 25 M. Pučić, A. Knežević, J. Vidič, B. Adamczyk, M. Novokmet, O. Polašek, O. Gornik, S. Šupraha-Goreta, M. R. Wormald, I. Redžić, H. Campbell, A. Wright, N. D. Hastie, J. F. Wilson, I. Rudan, M. Wuhrer, P. M. Rudd, D. Josić and G. Lauc, High Throughput Isolation and Glycosylation Analysis of Ig-Variability and Heritability of the IgG Glycome in Three Isolated Human Populations, *Mol. Cell. Proteomics*, 2011, 10(10), M111.010090, DOI: 10.1074/MCP.M111.010090.
- 26 W. E. Johnson, C. Li and A. Rabinovic, Adjusting batch effects in microarray expression data using empirical Bayes methods, *Biostatistics*, 2007, **8**(1), 118–127, DOI: 10.1093/ biostatistics/kxj037.
- J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe and J. D. Storey, The sva package for removing batch effects and other unwanted variation in high-throughput experiments, *Bioinformatics*, 2012, 28(6), 882–883, DOI: 10.1093/bioinformatics/bts034.
- 28 M. C. Galligan, R. Saldova, M. P. Campbell, P. M. Rudd and T. B. Murphy, Greedy feature selection for glycan chromatography data with the generalized Dirichlet distribution, *BMC Bioinf.*, 2013, 14, 155.
- 29 J. Aitchison, Principal component analysis of compositional data, *Biometrika*, 1983, **70**(1), 57–65.
- 30 W. Lin, P. Shi, R. Feng and H. Li, Variable selection in regression with compositional covariates, *Biometrika*, 2014, **101**(4), 785–797.
- 31 J. Aitchison and J. Bacon-Shone, Log contrast models for experiments with mixtures, *Biometrika*, 1984, **71**, 323–330.
- 32 J. J. Houwing-Duistermaat, H. W. Uh and A. Gusnanto, Discussion on the paper 'Statistical contributions to bioinformatics: design, modelling, structure learning and integration' by Jeffrey S. Morris and Veerabhadran Baladandayuthapani, *Stat. Modell.*, 2017, **17**(4–5), 319–326, DOI: 10.1177/1471082x17706135.